Adenovirus-specific CD4+ T cell clones recognizing endogenous antigen inhibit viral replication in vitro through cognate interaction

Journal of Immunology

Volumn 177, Issue 12, 2006, Pages 8851-8859

  Heemskerk, Bianca ^a,b   Van Vreeswijk, Tamara ^a   Veltrop Duits, Louise A ^a   Sombroek, Claudia C ^a   Franken, Kees ^a   Verhoosel, Renate M ^a   Hiemstra, Pieter S ^a   Van Leeuwen, Daphne ^a   Ressing, Maaike E ^a   Toes, René E M ^a   Van Tol, Maarten J D ^a   Schilham, Marco W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 2; PERFORIN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN RECOGNITION; ARTICLE; BRONCHUS MUCOSA; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HUMAN; HUMAN ADENOVIRUS; HUMAN CELL; IN VITRO STUDY; INFECTIOUS COMPLICATION; LYMPHOCYTE CLONE; LYMPHOCYTE TRANSFORMATION; MELANOMA CELL; PRIORITY JOURNAL; SEROTYPE; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 33845441550     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.12.8851     Document Type: Article

References (71)

1. Hierholzer, J. 1992. Adenoviruses in the immunocompromised host. Clin. Microbiol. Rev. 5: 262-274.
2. Ljungman, P. 1997. Respiratory virus infections in bone marrow transplant recipients: the European perspective. Am. J. Med. 102: 44-47.
3. Hale, G. A., H. E. Heslop, R. A. Krance, M. A. Brenner, D. Jayawardene, D. K. Srivastava, and C. C. Patrick. 1999. Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant. 23: 277-282.
4. Baldwin, A., H. Kingman, M. Darville, A. B. Foot, D. Grier, J. M. Cornish, N. Goulden, A. Oakhill, D. H. Pamphilon, C. G. Steward, and D. I. Marks. 2000. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant. 26: 1333-1338.
5. Runde, V., S. Ross, R. Trenschel, E. Lagemann, O. Basu, K. Renzing-Kohler, U. W. Schaefer, M. Roggendorf, and E. Holler. 2001. Adenoviral infection after allogeneic stem cell transplantation (SCT): report on 130 patients from a single SCT unit involved in a prospective multi center surveillance study. Bone Marrow Transplant. 28: 51-57.
6. Kojaoghlanian, T., P. Flomenberg, and M. S. Horwitz. 2003. The impact of adenovirus infection on the immunocompromised host. Rev. Med. Virol. 13: 155-171.
7. Heemskerk, B., A. C. Lankester, T. van Vreeswijk, M. F. Beersma, E. C. Claas, L. A. Veltrop-Duits, A. C. Kroes, J. M. Vossen, M. W. Schilham, and M. J. van Tol. 2005. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J. Infect. Dis. 191: 520-530.
8. Chakrabarti, S., V. Mautner, H. Osman, K. E. Collingham, C. D. Fegan, P. E. Klapper, P. A. Moss, and D. W. Milligan. 2002. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 100: 1619-1627.
9. van Tol, M. J., A. C. Kroes, J. Schinkel, W. Dinkelaar, E. C. Claas, C. M. Jol-Van Der Zijde, and J. M. Vossen. 2005. Adenovirus infection in paediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery. Bone Marrow Transplant. 36: 39-50.
10. Echavarria, M., M. Forman, M. J. van Tol, J. M. Vossen, P. Charache, and A. C. Kroes. 2001. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet 358: 384-385.
11. Schilham, M. W., E. C. Claas, W. van Zaane, B. Heemskerk, J. M. Vossen, A. C. Lankester, R. E. Toes, M. Echavarria, A. C. Kroes, and M. J. van Tol. 2002. High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation. Clin. Infect. Dis. 35: 526-532.
12. Lankester, A. C., M. J. van Tol, E. C. Claas, J. M. Vossen, and A. C. Kroes. 2002. Quantification of adenovirus DNA in plasma for management of infection in stem cell graft recipients. Clin. Infect. Dis. 34: 864-867.
13. Lion, T., R. Baumgartinger, F. Watzinger, S. Matthes-Martin, M. Suda, S. Preuner, B. Futterknecht, A. Lawitschka, C. Peters, U. Potschger, and H. Gadner. 2003. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 102: 1114-1120.
14. Leruez-Ville, M., V. Minard, F. Lacaille, A. Buzyn, E. Abachin, S. Blanche, F. Freymuth, and C. Rouzioux. 2004. Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection. Clin. Infect. Dis. 38: 45-52.
15. Horwitz, M. S. 2001. Adenoviruses. In Fields' Virology. D. M. Knipe and P. M. Howley, eds. Lippincott Williams & Wilkins, Philadelphia, pp. 2301-2326.
16. De Jong, J. C., A. G. Wermenbol, M. W. Verweij-Uijterwaal, K. W. Slaterus, P. Wertheim-Van Dillen, G. J. Van Doornum, S. H. Khoo, and J. C. Hierholzer. 1999. Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J. Clin. Microbiol. 37: 3940-3945.
17. Flomenberg, P., J. Babbitt, W. R. Drobyski, R. C. Ash, D. R. Carrigan, G. V. Sedmak, T. McAuliffe, B. Camitta, M. M. Horowitz, N. Bunin, et al. 1994. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J. Infect. Dis. 169: 775-781.
18. Carrigan, D. R. 1997. Adenovirus infections in immunocompromised patients. Am. J. Med. 102: 71-74.
19. Flomenberg, P., V. Piaskowski, R. L. Truitt, and J. T. Casper. 1995. Characterization of human proliferative T cell responses to adenovirus (see comments). J. Infect. Dis. 171: 1090-1096.
20. Ljungman, P. 2004. Treatment of adenovirus infections in the immunocompromised host. Eur. J. Clin. Microbiol. Infect. Dis. 23: 583-588.
21. Walter, E. A., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. Thomas, and S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333: 1038-1044.
22. Heslop, H. E., and C. M. Rooney. 1997. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol. Rev. 157: 217-222.
23. Einsele, H., E. Roosnek, N. Rufer, C. Sinzger, S. Riegler, J. Loffler, U. Grigoleit, A. Moris, H. G. Rammensee, L. Kanz, et al. 2002. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99: 3916-3922.
24. Hromas, R., K. Cornetta, E. Srour, C. Blanke, and E. R. Broun. 1994. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T cell depleted bone marrow transplantation. Blood 84: 1689-1690.
25. Chakrabarti, S., K. E. Collingham, C. D. Fegan, D. Pillay, and D. W. Milligan. 2000. Adenovirus infeclions following haematopoietic cell transplantation: is there a role for adoptive immunotherapy? Bone Marrow Transplant. 26: 305-307.
26. Smith, C. A., L. S. Woodruff, G. R. Kitchingman, and C. Rooney. 1996. Adenovirus-pulsed dendrilic cells stimulate human virus-specific T-cell responses in vitro. J. Virol. 70: 6733-6740.
27. Souberbielle, B. E., and W. C. Russell. 1995. Human T cell proliferative responses to polypeptides from Adenovirus type 2. J. Infect. Dis. 172: 1421-1422.
28. + T-cell responses from healthy adulls. Viral Immunol. 14: 403-413.
29. + T-cell epitope. Hum. Gene Ther. 13: 1167-1178.
30. Leen, A. M., U. Sili, B. Savoldo, A. M. Jewell, P. A. Piedra, M. K. Brenner, and C. M. Rooney. 2004. Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood 103: 1011-1019.
31. + adenovirus-specific T cells: implications for immunotherapy and gene therapy. J. Virol. 77: 6562-6566.
32. + T cells. Blood 104: 2432-2440.
33. + cytotoxic T cell responses to adenovirus capsid proteins. Virology 350: 312-322.
34. Schagen, F. H., A. C. Moor, S. C. Cheong, S. J. Cramer, H. van Ormondt, A. J. van der Eb, T. M. Dubbelman, and R. C. Hoeben. 1999. Photodynamic treatment of adenoviral vectors with visible light: an easy and convenient method for viral inactivation. Gene Ther. 6: 873-881.
35. Kinsella, T. M., and G. P. Nolan. 1996. Episomal vectors rapidly and stably produce high-liter recombinant retrovirus. Hum. Gene Ther. 7: 1405-1413.
36. van Wetering, S., A. C. van der Linden, M. A. van Sterkenburg, K. F. Rabe, J. Schalkwijk, and P. S. Hiemstra. 2000. Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase. J. Investig. Med. 48: 359-366.
37. + T cells stimulated by conserved adenovirus 5 hexon peptides recognize cells infected with different species of human adenovirus. Eur. J. Immunol. 36: 2410-2423.
38. Scott-Taylor, T. H., and G. W. Hammond. 1992. Conserved sequences of the adenovirus genome for detection of all human adenovirus types by hybridization. J. Clin. Microbiol. 30: 1703-1710.
39. Rux, J. J., and R. M. Burnett. 2000. Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon. Mol. Ther. 1: 18-30.
40. Tang, J., M. Olive, K. Champagne, N. Flomenberg, L. Eisenlohr, S. Hsu, and P. Flomenberg. 2004. Adenovirus hexon T-cell epitope is recognized by most adults and is restricted by HLA DP4, the most common class II allele. Gene Ther. 11: 1408-1415.
41. Regn, S., S. Raffegerst, X. Chen, D. Schendel, H. J. Kolb, and M. Roskrow. 2001. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant. Bone Marrow Transplant. 27: 53-64.
42. Smyth, M. J., J. M. Kelly, V. R. Sutton, J. E. Davis, K. A. Browne, T. J. Sayers, and J. A. Trapani. 2001. Unlocking the secrets of cytotoxic granule proteins. J. Leukocyte Biol. 70: 18-29.
43. Shresta, S., C. T. Pham, D. A. Thomas, T. A. Graubert, and T. J. Ley. 1998. How do cytotoxic lymphocytes kill their targets? Curr. Opin. Immunol. 10: 581-587.
44. + T cell-mediated cytotoxicity. J. Immunol. 162: 2639-2647.
45. Kataoka, T., N. Shinohara, H. Takayama, K. Takaku, S. Kondo, S. Yonehara, and K. Nagai. 1996. Concanamycin A, a powerful tool for characterization and estimation of contribution of perform- and Fas-based lytic pathways in cell-mediated cytotoxicity. J. Immunol. 156: 3678-3686.
46. Sester, M., U. Sester, S. A. Salvador, G. Heine, S. Lipfert, M. Girndt, B. Gartner, and H. Kohler. 2002. Age-related decrease in adenovirus-specific T cell responses. J. Infect. Dis. 185: 1379-1387.
47. Smith, C. A., L. S. Woodruff, C. Rooney, and G. R. Kitchingman. 1998. Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. Hum. Gene Ther. 9: 1419-1427.
48. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
49. Adhikary, D., U. Behrends, A. Moosmann, K. Witter, G. W. Bornkamm, and J. Mautner. 2006. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J. Exp. Med. 203: 995-1006.
50. Brown, D. M., E. Roman, and S. L. Swain. 2004. CD4 T cell responses to influenza infection. Semin. Immunol. 16: 171-177.
51. Moore, M. L., E. L. McKissic, C. C. Brown, J. E. Wilkinson, and K. R. Spindler. 2004. Fatal disseminated mouse adenovirus type 1 infection in mice lacking B cells or Bruton's tyrosine kinase. J. Virol. 78: 5584-5590.
52. Moore, M. L., C. C. Brown, and K. R. Spindler. 2003. T cells cause acute immunopathology and are required for long-term survival in mouse adenovirus type 1-induced encephalomyelitis. J. Virol. 77: 10060-10070.
53. Lavery, D., S. M. Fu, T. Lufkin, and S. Chen-Kiang. 1987. Productive infection of cultured human lymphoid cells by adenovirus. J. Virol. 61: 1466-1472.
54. Boss, J. M., and P. E. Jensen. 2003. Transcriptional regulation of the MHC class II antigen presentation pathway. Curr. Opin. Immunol. 15: 105-111.
55. + T-cell differentiation in response to viruses. Nat. Rev. Immunol. 3: 931-939.
56. + T cells. Virology 287: 79-88.
57. + CTL directed against herpes simplex virus-infected cells. J. Immunol. 162: 6100-6106.
58. +-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J. Virol. 77: 12088-12104.
59. + T lymphocytes. J. Immunol. 169: 1293-1301.
60. + CTLs ex vivo. J. Immunol. 168: 5954-5958.
61. + T lymphocytes: analysis using the combination of hereditary perforin-deficient effector cells and Fas-deficient target cells. J. Immunol. 170: 2205-2213.
62. Wold, W. S., K. Doronin, K. Toth, M. Kuppuswamy, D. L. Lichtenstein, and A. E. Tollefson. 1999. Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr. Opin. Immunol. 11: 380-386.
63. Tollefson, A. E., T. W. Hermiston, D. L. Lichtenstein, C. F. Colle, R. A. Tripp, T. Dimitrov, K. Toth, C. E. Wells, P. C. Doherty, and W. S. Wold. 1998. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature 392: 726-730.
64. + CTL. J. Exp. Med. 202: 1109-1119.
65. Mukherjee, P., A. Dani, S. Bhatia, N. Singh, A. Y. Rudensky, A. George, V. Bal, S. Mayor, and S. Rath. 2001. Efficient presentation of both cytosolic and endogenous transmembrane protein antigens on MHC class II is dependent on cytoplasmic proteolysis. J. Immunol. 167: 2632-2641.
66. Tewari, M. K., G. Sinnathamby, D. Rajagopal, and L. C. Eisenlohr. 2005. A cytosolic pathway for MHC class II-restricted antigen processing that is proteasome and TAP dependent. Nat. Immunol. 6: 287-294.
67. Lich, J. D., J. F. Elliott, and J. S. Blum. 2000. Cytoplasmic processing is a prerequisite for presentation of an endogenous antigen by major histocompatibility complex class II proteins. J. Exp. Med. 191: 1513-1524.
68. Dani, A., A. Chaudhry, P. Mukherjee, D. Rajagopal, S. Bhatia, A. George, V. Bal, S. Rath, and S. Mayor. 2004. The pathway for MHCII-mediated presentation of endogenous proteins involves peptide transport to the endoy-lysosomal compartment. J. Cell Sci. 117: 4219-4230.
69. Paludan, C., D. Schmid, M. Landthaler, M. Vockerodt, D. Kube, T. Tuschl, and C. Munz. 2005. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307: 593-596.
70. Landais, E., X. Saulquin, M. Bonneville, and E. Houssaint. 2005. Long-term MHC class II presentation of the EBV lytic protein BHRF1 by EBV latently infected b cells following capture of BHRF1 antigen. J. Immunol. 175: 7939-7946.
71. + cytotoxic T cells against mouse hepatitis virus A59. Immunology 84: 521-527.